170 related articles for article (PubMed ID: 11754416)
1. Methods for estimation of bone marrow plasma cell involvement in myeloma: predictive value for response and survival in patients undergoing autologous stem cell transplantation.
Rajkumar SV; Fonseca R; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Therneau TM; Kyle RA; Greipp PR; Gertz MA
Am J Hematol; 2001 Dec; 68(4):269-75. PubMed ID: 11754416
[TBL] [Abstract][Full Text] [Related]
2. Effect of complete response on outcome following autologous stem cell transplantation for myeloma.
Rajkumar SV; Fonseca R; Dispenzieri A; Lacy MQ; Witzig TE; Lust JA; Larson D; Therneau TM; Kyle RA; Litzow MR; Greipp PR; Gertz MA
Bone Marrow Transplant; 2000 Nov; 26(9):979-83. PubMed ID: 11100277
[TBL] [Abstract][Full Text] [Related]
3. Impact of pre-transplant bone marrow plasma cell percentage on post-transplant response and survival in newly diagnosed multiple myeloma.
Chakraborty R; Muchtar E; Kumar SK; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
Leuk Lymphoma; 2017 Feb; 58(2):308-315. PubMed ID: 27390076
[TBL] [Abstract][Full Text] [Related]
4. Impact of bone marrow plasma cells percentage on survival at diagnosis and pre-transplant period in newly diagnosed multiple myeloma: Experience of a single center from Turkey.
Ciftciler R; Goker H; Buyukasık Y; Aladag E; Saglam EA; Demiroglu H
Transfus Apher Sci; 2019 Jun; 58(3):313-317. PubMed ID: 30928228
[TBL] [Abstract][Full Text] [Related]
5. The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell Transplantation.
Dittus C; Uwumugambi N; Sun F; Sloan JM; Sanchorawala V
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1729-1732. PubMed ID: 27296954
[TBL] [Abstract][Full Text] [Related]
6. Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma.
Rajkumar SV; Fonseca R; Lacy MQ; Witzig TE; Therneau TM; Kyle RA; Litzow MR; Gertz MA; Greipp PR
J Clin Oncol; 1999 May; 17(5):1551-7. PubMed ID: 10334543
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic form.
Rago A; Grammatico S; Za T; Levi A; Mecarocci S; Siniscalchi A; De Rosa L; Felici S; Bongarzoni V; Piccioni AL; La Verde G; Pisani F; Franceschini L; Paviglianiti AL; Caravita T; Petrucci MT; De Stefano V; Cimino G;
Cancer; 2012 Nov; 118(22):5544-9. PubMed ID: 22786730
[TBL] [Abstract][Full Text] [Related]
8. Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma.
Rajkumar SV; Fonseca R; Dewald GW; Therneau TM; Lacy MQ; Kyle RA; Greipp PR; Gertz MA
Cancer Genet Cytogenet; 1999 Aug; 113(1):73-7. PubMed ID: 10459351
[TBL] [Abstract][Full Text] [Related]
9. Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients.
Al Saleh AS; Parmar HV; Visram A; Muchtar E; Buadi FK; Go RS; Dispenzieri A; Kapoor P; Warsame R; Lacy MQ; Dingli D; Leung N; Gonsalves WI; Kourelis TV; Gertz MA; Kyle RA; Rajkumar SV; Kumar SK
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):596-601. PubMed ID: 32360276
[TBL] [Abstract][Full Text] [Related]
10. Bone marrow plasma cell assessment before peripheral blood stem cell mobilization in patients with multiple myeloma undergoing autologous stem cell transplantation.
Lee SE; Yoon JH; Shin SH; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Lee JW; Min WS; Park CW; Kim M; Min CK
Biomed Res Int; 2014; 2014():982504. PubMed ID: 24895639
[TBL] [Abstract][Full Text] [Related]
11. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
12. Biological properties of bone marrow plasma cells influence their recovery in aspirate specimens: impact on classification of plasma cell disorders and potential bias to evaluation of treatment response.
Demyanets S; Kaider A; Simonitsch-Klupp I; Bayer G; Subasic A; Thalhammer R; Esterbauer H; Krauth MT; Agis H; Reiter T; Schwarzinger I
Ann Hematol; 2020 Nov; 99(11):2599-2609. PubMed ID: 32935190
[TBL] [Abstract][Full Text] [Related]
13. The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation.
Patriarca F; Carobolante F; Zamagni E; Montefusco V; Bruno B; Englaro E; Nanni C; Geatti O; Isola M; Sperotto A; Buttignol S; Stocchi R; Corradini P; Cavo M; Fanin R
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1068-73. PubMed ID: 25754658
[TBL] [Abstract][Full Text] [Related]
14. Cell proliferation of myeloma plasma cells: comparison of the blood and marrow compartments.
Kumar S; Rajkumar SV; Greipp PR; Witzig TE
Am J Hematol; 2004 Sep; 77(1):7-11. PubMed ID: 15307099
[TBL] [Abstract][Full Text] [Related]
15. [Clinical Features and Prognostic Factors of Patients with Multiple Myeloma].
Gong YY; Yan XS; Wang YM; Pan JL; Zhai YY; Chen SN; Liu DD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Jun; 29(3):772-780. PubMed ID: 34105471
[TBL] [Abstract][Full Text] [Related]
16. Combined evaluation of bone marrow aspirate and biopsy is superior in the prognosis of multiple myeloma.
Stifter S; Babarović E; Valković T; Seili-Bekafigo I; Stemberger C; Nacinović A; Lucin K; Jonjić N
Diagn Pathol; 2010 May; 5():30. PubMed ID: 20482792
[TBL] [Abstract][Full Text] [Related]
17. Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: a retrospective study.
Liu H; Yuan C; Heinerich J; Braylan R; Chang M; Wingard J; Moreb J
Leuk Lymphoma; 2008 Feb; 49(2):306-14. PubMed ID: 18231918
[TBL] [Abstract][Full Text] [Related]
18. Beta2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma.
Rajkumar SV; Fonseca R; Lacy MQ; Witzig TE; Lust JA; Greipp PR; Therneau TM; Kyle RA; Litzow MR; Gertz MA
Bone Marrow Transplant; 1999 Jun; 23(12):1261-6. PubMed ID: 10414913
[TBL] [Abstract][Full Text] [Related]
19. A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death.
Steensma DP; Gertz MA; Greipp PR; Kyle RA; Lacy MQ; Lust JA; Offord JR; Plevak MF; Therneau TM; Witzig TE
Blood; 2001 Apr; 97(8):2522-3. PubMed ID: 11290618
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow biopsy in monoclonal gammopathies: correlations between pathological findings and clinical data. The Cooperative Group for Study and Treatment of Multiple Myeloma.
Riccardi A; Ucci G; Luoni R; Castello A; Coci A; Magrini U; Ascari E
J Clin Pathol; 1990 Jun; 43(6):469-75. PubMed ID: 2199532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
